Cited by 658Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease<subtitle>A Randomized Controlled Trial</subtitle>

Open access

Green, Robert C.·2009·JAMA

DOI 10.1001/jama.2009.1866PMC PMC2902875

Open this paper in CoChat — free account

Abstract

CONTEXT: Amyloid-beta peptide (Abeta(42)) has been implicated in the pathogenesis of Alzheimer disease (AD). Tarenflurbil, a selective Abeta(42)-lowering agent, demonstrated encouraging results on cognitive and functional outcomes among mildly affected patients in an earlier phase 2 trial. OBJECTIVE: To determine the efficacy, safety, and tolerability of tarenflurbil. DESIGN, SETTING, AND PATIENTS: A multicenter, randomized, double-blind, placebo-controlled trial enrolling patients with mild AD was conducted at 133 trial sites in the United States between February 21, 2005, and April 30, 2008. Concomitant treatment with cholinesterase inhibitors or memantine was permitted. INTERVENTION: Tarenflurbil, 800 mg, or placebo, administered twice a day. MAIN OUTCOME MEASURES: Co-primary efficacy end points were the change from baseline to month 18 in total score on the subscale of the Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog, 80-point version) and Alzheimer Disease Cooperative Studies-activities of daily living (ADCS-ADL) scale. Additional prespecified slope analyses explored the possibility of disease modification. RESULTS: Of the 1684 participants randomized, 1649 were included in the analysis, and 1046 completed the trial. Tarenflurbil had no beneficial effect on the co-primary outcomes (difference in change from baseline to month 18 vs placebo, based on least squares means: 0.1 for ADAS-Cog; 95% CI, -0.9 to 1.1; P = .86 and -0.5 for ADCS-ADL; 95% CI, -1.9 to 0.9; P = .48) using an intent-to-treat analysis. No significant differences occurred in the secondary outcomes. The ADAS-Cog score decreased by 7.1 points over 18 months. The tarenflurbil group had a small increase in frequency of dizziness, anemia, and infections. CONCLUSION: Tarenflurbil did not slow cognitive decline or the loss of activities of daily living in patients with mild AD. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00105547.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jama.2009.1866

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
[Japanese version of the Neuropsychiatric Inventory--a scoring system for neuropsychiatric disturbance in dementia patients].
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,010
Special Care Units and Traditional Care in Dementia: Relationship with Behavior, Cognition, Functional Status and Quality of Life - A Review
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,851
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,006
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175

Show all 44 references

Sorted by citations

Items 601–658 of 658

Le tarenflurbil peu efficace contre la progression d’Alzheimer
(2010) · Actualités Pharmaceutiques Hospitalières · doi:10.1016/s1769-7344(10)70257-2
Proteins and Disease | The Chemistry of Alzheimer Disease – Molecular, Genetic and Physiologic Perspectives
Sack, G. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.21437-4
Alzheimer’s Disease
Grill, J. D., & Cummings, J. L. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139032445.022
References
(2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811351-6.00026-7
Antidementiva
Schwabe, U. (2010) · Springer eBooks · doi:10.1007/978-3-642-13380-0_10
Antidementiva
Schwabe, U. (2011) · Springer eBooks · doi:10.1007/978-3-642-21992-4_10
Alzheimer’s disease
Matthews, B. R. (2016) · Cambridge University Press eBooks · doi:10.1017/9781139924771.009
Antiamyloid therapy of Alzheimer’s disease: origins, current state and prospects of development
Vorobev, S. V., Emelin, А. Y., Yanishevskij, S. N., Kostina, E. V., & Galaeva, A. A. (2022) · Neurology Bulletin · doi:10.17816/nb108278
Aspartic Proteases of Alzheimer's Disease: β- and γ--Secretases
Wolfe, M. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.10077-x
Quantitative Metabolic Magnetic Resonance Imaging: A Case for Bioscales in Medicine
Thulborn, K. R. (2023) · Springer eBooks · doi:10.1007/978-3-031-10909-6_52
Alzheimer’s Disease and Constipation: A Two-Sample Bidirectional Mendelian Randomization Study
任, 招. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.143882
Additional file 3 of Prediction of differentially expressed microRNAs in blood as potential biomarkers for Alzheimer’s disease by meta-analysis and adaptive boosting ensemble learning
Yuen, S. C., Liang, X., Zhu, H., Jia, Y., & Leung, S.-W. (2021) · Figshare · doi:10.6084/m9.figshare.14945066
Additional file 2 of Prediction of differentially expressed microRNAs in blood as potential biomarkers for Alzheimer’s disease by meta-analysis and adaptive boosting ensemble learning
Yuen, S. C., Liang, X., Zhu, H., Jia, Y., & Leung, S.-W. (2021) · Figshare · doi:10.6084/m9.figshare.14945063
Additional file 1 of Prediction of differentially expressed microRNAs in blood as potential biomarkers for Alzheimer’s disease by meta-analysis and adaptive boosting ensemble learning
Yuen, S. C., Liang, X., Zhu, H., Jia, Y., & Leung, S.-W. (2021) · Figshare · doi:10.6084/m9.figshare.14945060
Chapter 43. Agents for Neurocognitive Disorders
Ayers, G. M., & Brown, F. W. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as43
γ-Secretase in the pathogenesis of Alzheimer’s disease and therapeutic potential of its modulators
Николаевич, В. В., Иванович, В. В., & Shabanov, P. D. (2024) · Психофармакология и биологическая наркология · doi:10.17816/phbn635851
Efficacy and Safety of DL-3-N-Butylphthalide in Patients with Mild Cognitive Impairment: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical TrialPreprint
Wang, P., Han, X., Yu, Y., Zhou, Y., Ma, Q., Lv, P., Li, W., Zhang, J., Jiang, H., Zhang, W., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5134448
A Novel Drug Delivery System Utilizing Nanoparticles to Treat Neurological Disorders
Singh, M. P., Waseem, A., Kumar, V., Prakash, R., Siddiqui, A. J., Prakash, A., & Raza, S. S. (2025) · Smart nanomaterials technology · doi:10.1007/978-981-96-2112-5_16
Harnessing the power of anti-amyloidogenic polyglutamine binding peptide 1: A computational and biophysical approach to antimicrobial prediction
Ramos‐Martín, F., Peltier, F., Oueslati, S., Cousin, L., Rima, M., Perret, M., Bibens, L., Sevin, E., Antonietti, V., Nascimento, S. D., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.144938
Translational Approaches Toward Neuroscience
Atale, N., Akolkar, H., & Rani, V. (2025) · Advances in Science, Technology & Innovation/Advances in science, technology & innovation · doi:10.1007/978-3-031-80973-6_4
Amyloid β hypothesis in the development of therapeutic agents for Alzheimer's disease
Adeniji, A. O., Johnson, C., & Mody, V. V. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30008-0.00020-x
Hur bra är våra läkemedel vid Alzheimers sjukdom och vad kan vi förvänta oss av morgondagens
Morén, L. (2012) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Additional file 1 of Truncated mini LRP1 transports cargo from luminal to basolateral side across the blood brain barrier
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049039
Additional file 6 of Truncated mini LRP1 transports cargo from luminal to basolateral side across the blood brain barrier
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049054
Additional file 8 of Truncated mini LRP1 transports cargo from luminal to basolateral side across the blood brain barrier
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049060
Additional file 4 of Truncated mini LRP1 transports cargo from luminal to basolateral side across the blood brain barrier
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049048
Additional file 5 of Truncated mini LRP1 transports cargo from luminal to basolateral side across the blood brain barrier
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049051
Additional file 3 of Truncated mini LRP1 transports cargo from luminal to basolateral side across the blood brain barrier
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049045
Additional file 9 of Truncated mini LRP1 transports cargo from luminal to basolateral side across the blood brain barrier
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049063
Additional file 2 of Truncated mini LRP1 transports cargo from luminal to basolateral side across the blood brain barrier
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049042
Additional file 7 of Truncated mini LRP1 transports cargo from luminal to basolateral side across the blood brain barrier
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049057
Additional file 1 of Blood–brain barrier penetration prediction enhanced by uncertainty estimation
Tong, X., Wang, D., Ding, X., Tan, X., Ren, Q., Chen, G., Rong, Y., Xu, T., Huang, J., Jiang, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20267401
Recent Advances and Strategies in Drug Repurposing for Alzheimer’s Disease Therapy
Kim, S., Woo, H., Chae, S., & Kim, J. E. (2025) · KSBB Journal · doi:10.7841/ksbbj.2025.40.4.327
Implication du complexe récepteur 5-HT4/APP/ADAM10 dans la voie non-amyloïdogénique de la maladie d’Alzheimer
Cochet, M. (2011) · theses.fr (ABES) · doi:10.70675/599a8bbez3c0bz407dzbd52z0872ed5f8f6d
Validation préclinique de l'efficacité de l'ANAVEX2-73 dans des modèles transgénique et non transgénique de la maladie d'Alzheimer
Lahmy, V. (2014) · theses.fr (ABES) · doi:10.70675/23744d67zb26bz4a32zadbfz3931ecca70f5
Impact de l’infection à Helicobacter pylori sur la maladie d’Alzheimer
Baudron, C. R. (2014) · theses.fr (ABES) · doi:10.70675/201f68e4z646cz4e66z80e2zd8a4b726fbe7
Mobilisation de l'acide arachidonique et sensibilité au peptide ß-amyloïde
Thomas, M. H. (2015) · theses.fr (ABES) · doi:10.70675/904987d5zc8c8z4104z95dfz2f7e680d8be3
Virus Herpès Simplex de type 1 : une cible potentielle pour la prévention de la maladie d’Alzheimer ?
Linard, M. (2021) · theses.fr (ABES) · doi:10.70675/792b3731z2670z4aedza18ezcd3259857759
Dysfonctionnement de l'aire CA2 de l'hippocampe et déficits de mémoire sociale dans un modèle murin de la maladie d'Alzheimer
Rey, C. C. (2020) · theses.fr (ABES) · doi:10.70675/4bc74e03zfa3az49e6zb5aaz35059441853a
Physiological and pathological roles of the amyloid precursor protein at the presynapse
Jordá-Siquier, T. (2021) · theses.fr (ABES) · doi:10.70675/3bff9a77z3935z4d28zb02bz5b454bcbc77e
Stratégies de ré-analyse d'un essai de prévention du déclin des fonctions cognitives non concluant
Bougel, C. (2020) · theses.fr (ABES) · doi:10.70675/9f920116z1378z4232z8590z40226aa8975f
Insight into the specificity of antimicrobial peptides towards biological membranes as studied by bioinformatics and experimental biophysics
Ramos‐Martín, F. (2021) · theses.fr (ABES) · doi:10.70675/1ce5f4c2z985cz4727zbb4az35a0be6dd690
Comparative efficacy and safety of pathway-targeted pharmacotherapies for Alzheimer’s disease: A systematic review and network meta-analysis of phase III trials
Wu, Y., Di, Y., Wang, H. W., Wang, L., Zhang, J., Zhang, Y., & Lyu, D. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103216
Recruitment and retention of older people with dementia in clinical trials focused on evaluating the pharmacological management of the cognitive symptoms of dementia: a scoping review
Shawaqfeh, B., Hughes, C. M., McGuinness, B., & Barry, H. E. (2026) · International Journal of Pharmacy Practice · doi:10.1093/ijpp/riag107
BindingDB Entry 50033795: SAR studies of acidic dual¿-secretase/PPAR¿ modulators.
BindingDB (2012) · UC San Diego · doi:10.7270/q2jq11d0
BindingDB Entry 50042653: Further characterization of a putative serine protease contributing to the¿-secretase cleavage ofß-amyloid precursor protein.
BindingDB (2013) · UC San Diego · doi:10.7270/q2765gph
BindingDB Entry 50018480: A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery.
BindingDB (2024) · UC San Diego · doi:10.7270/q2639tzd
BindingDB Entry 50007047: Highly Selective Butyrylcholinesterase Inhibitors with Tunable Duration of Action by Chemical Modification of Transferable Carbamate Units Exhibit Pronounced Neuroprotective Effect in an Alzheimer's Disease Mouse Model.
BindingDB (2021) · UC San Diego · doi:10.7270/q2m3301t
BindingDB Entry 50002402: Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead.
BindingDB (2020) · UC San Diego · doi:10.7270/q2g73hcn
BindingDB Entry 50043941: Design, synthesis, and pharmacological evaluation of a novel series of pyridopyrazine-1,6-dione¿-secretase modulators.
BindingDB (2014) · UC San Diego · doi:10.7270/q2tb18dk
BindingDB Entry 50004772: Initial Optimization of a New Series of γ-Secretase Modulators Derived from a Triterpene Glycoside.
BindingDB (2020) · UC San Diego · doi:10.7270/q29g5qps
BindingDB Entry 50042999: Progress and developments in tau aggregation inhibitors for Alzheimer disease.
BindingDB (2014) · UC San Diego · doi:10.7270/q2ht2qqd
BindingDB Entry 50009793: Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
BindingDB (2021) · UC San Diego · doi:10.7270/q2sx6hph
BindingDB Entry 50045439: SAR-studies of¿-secretase modulators with PPAR¿-agonistic and 5-lipoxygenase-inhibitory activity for Alzheimer's disease.
BindingDB (2016) · UC San Diego · doi:10.7270/q2280989
BindingDB Entry 50043116: Membrane anchoring¿-secretase modulators with terpene-derived moieties.
BindingDB (2014) · UC San Diego · doi:10.7270/q2df6smp
Discovery of Nivegacetor, an Advanced γ-Secretase Modulator, for the Treatment of Alzheimer’s Disease
Sarmiento, R. M. R., Ratni, H., Reutlinger, M., Pichereau, S., Vifian, W., Gerlach, I., Lindemann, L., & Baumann, K. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01762
From molecular pathways to nanocarrier design: a translational framework for lipid-based nanoparticles in Alzheimer’s disease
Manna, P., Maity, A., Roy, S., Sahu, S., Pradhan, S., Ganguly, S. C., Chakraborty, M., & Kundu, M. (2026) · Discover Nano · doi:10.1186/s11671-026-05124-1
Farmakoterapia dysfunkcji poznawczych w chorobie Alzheimera: obecne strategie i terapie eksperymentalne
Sobów, T. (2013) · DOAJ (DOAJ: Directory of Open Access Journals)

Authors: Green, R. C.
Affiliations: Boston University (US)
Corresponding author: Green, Robert C.
ORCID: Green, Robert C.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2009-12-16
Volume: 302
Issue: 23
Pages: 2557
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.2009.1866
PMC: PMC2902875
OpenAlex: W1982816514
Cited by: 643
References: 44
Citations by year: 2026: 11 · 2025: 25 · 2024: 39 · 2023: 22 · 2022: 28 · 2021: 32 · 2020: 43 · 2019: 32 · 2018: 26 · 2017: 40 · 2016: 40 · 2015: 31 · 2014: 44 · 2013: 52 · 2012: 63
FWCI: 38.79
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: JAMA (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: University of Pennsylvania
National Institute for Health and Care Research
National Institutes of Health (RR00533, HG02213, AG13846)
National Institute on Aging (P30AG008051, K24AG027841, P50AG005142, P30AG013846, P30-AG13846))
National Human Genome Research Institute (R01HG002213, R01 HG02213)
National Center for Research Resources (M01-RR-00533, M01RR000533)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords: Alzheimer's disease, mild Alzheimer disease, cognitive decline, activities of daily living, disease modification, ADAS-Cog, drug safety and efficacy, dizziness, anemia, infection
MeSH terms: Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Cognition, Cognition Disorders, Double-Blind Method, Enzyme Inhibitors, Female, Flurbiprofen, Humans, Male, Middle Aged, Peptide Fragments, Amyloid beta-Peptides, Amyloid Precursor Protein Secretases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease<subtitle>A Randomized Controlled Trial</subtitle>

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks